Cancer is a disease which does not discriminate, which explains why it is the second most leading cause of death the world over. Consequently, extensive research is being undertaken globally to understand how this disease, in its many forms, evolves. By understanding the fundamentals of the disease, we can hope to create new treatments and preventative measures to cure and control it. Biomaterials, in this regard, have proven efficacy in the treatment of disease, offering a platform for the delivery of drugs, gene therapies, and cells. Biomaterials come in a plethora of forms, such as biodegradable implants, nanofibers, injectable gels, or microneedles. These biomaterials can be either natural, synthetic, or a blend of polymers, which allow for disease targeting  co-delivery of multiple agents, and controlled therapeutic release. Despite all of this, the translation of biomaterials into the clinic is frustratingly uncommon. With the vast potential of these biomaterials, coupled with the immense global research community, it is essential that new methodologies to improve the approach to biomaterial cancer research are disseminated, and clinical translation made more tangible. This collection, therefore, will focus on new methods for the use of biomaterials in the prevention and treatment of cancers. Papers are particularly welcome on the development of biomaterials for the improved in vitro representation of cancers; biomaterials with immune therapy potential, including cell therapies and vaccines; and biomaterials as gene therapy platforms.